Efficacy of trastuzumab beyond progression as second-line chemotherapy for HER2-positive advanced gastric cancer
Gastrointestinal Cancer: Targets and Therapy Dec 07, 2017
Sato Y, et al. - Researchers here aimed at assessing the efficacy of trastuzumab beyond progression (TBP) as the second-line chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Findings revealed no survival benefit with TBP for HER2-positive AGC in patients with tumors refractory to trastuzumab-containing first-line therapies.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
